论文信息 - Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination - 字舞流文

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

A. Carneiro | G. Long | L. Ny | C. Krepler | I. Márquez-Rodas | L. de la Cruz-Merino | V. Atkinson | M. Khattak | A. Spreafico | S. Jang | C. L. Cowey | Scott J. Diede | Alan D. Smith | C. Mihalcioiu | T. Petrella | A. Berrocal | A. Arance | N. Hawk | A. Mant | Ke Chen | R. Jamal | F. Costa Svedman | C. Cowey